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ABSTRACT 
Context: A recent large-scale analysis of non-synonymous coding polymorphisms 
showed strong evidence that an alanine to threonine amino acid change at codon 946 of 
the interferon-induced helicase (IFIH1) gene (SNP ID rs1990760) was associated with 
type 1 diabetes. Previous investigations have also demonstrated that an intronic 
polymorphism (termed PD1.3; SNP ID rs11568821) in the programmed cell death 
(PDCD1) gene was associated with systemic lupus erythematosus and rheumatoid 
arthritis. 
Objective: We sought to replicate these genetic associations in Graves’ disease and 
autoimmune Addison’s disease patient cohorts. 
Patients and Methods: Six hundred and two Graves’ disease subjects, 214 Addison’s 
disease subjects and 446 healthy controls were genotyped for the IFIH1 and PDCD1 
single nucleotide polymorphisms using mass spectrometer analysis of primer extension 
products (Sequenom). 
Results: The alanine carrying allele at the IFIH1 codon 946 polymorphism was present in 
796 of 1204 (66%) GD patient alleles compared to 508 of 892 (57%) control subject 
alleles; odds ratio 1.47 (5-95% CI 1.23 to 1.76), p=1.9x10-5. In contrast, there was no 
association of alleles at this marker in autoimmune Addison’s disease. Neither was there 
evidence for association in either patient cohort at the PD1.3 polymorphism. 
Conclusions: We confirm a significant contribution of the Ala946Thr IFIH1 
polymorphism to organ-specific autoimmune diseases, extending the range of conditions 
associated with this variant to include Graves’ disease. This polymorphism may also 
contribute to several other autoimmune disorders. 
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INTRODUCTION 
There is a substantial contribution of genetic factors to the pathogenesis of autoimmune 
endocrine disorders (1,2), with one twin study suggesting that more than three-quarters of 
the predisposition to Graves’ disease (GD, autoimmune hyperthyroidism) is determined 
by heredity (3). Genomic loci that make a significant and consistent contribution to 
autoimmune thyroid disease (AITD) susceptibility include the Major Histocompatibility 
Complex, the cytotoxic T lymphocyte antigen-4 locus and an allele at the protein tyrosine 
phosphatase non-receptor 22 gene (encoding the lymphoid tyrosine phosphatase 620W 
variant) (1,2,4,5). These alleles have also been shown, in varying degrees, to have a role 
in type 1 diabetes (T1D), autoimmune Addison’s disease (AAD), rheumatoid arthritis and 
several other autoimmune conditions, demonstrating that several loci may be considered 
as common autoimmunity loci (1,2,5), presumably with a general predisposing effect to 
“skew” the immune response towards autoreactivity. These loci stand in contrast to 
disease specific loci, which tend to have a tissue-specific expression pattern, such as the 
insulin gene variable number tandem repeat (VNTR) polymorphism in T1D and the TSH-
receptor in GD (6-8). 
 
Recently, using preliminary results from large-scale association analysis of non-
synonymous single nucleotide polymorphisms (SNPs), a novel locus for T1D was 
identified, the interferon-induced helicase (IFIH1), also known as the melanoma 
differentiation-associated 5 (MDA-5) or Helicard gene (9). The IFIH1 gene encodes a 
viral RNA-activated apoptosis protein, with a putative role in sensing and triggering 
clearance responses in virally infected cells (10,11). Using a logistic regression analysis, 
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the most associated marker in IFIH1 was defined as the SNP rs1990760, which encodes 
an alanine to threonine amino acid change at codon 946, with an odds ratio for 
association with T1D of 1.16 (5-95% confidence interval 1.11- 1.22) for the major allele 
(9). Another molecule with a role in cellular apoptosis pathways that has been 
demonstrated to have a role in autoimmunity is the cell-surface programmed cell death 1 
receptor, encoded by the PDCD1 gene. Several large studies have shown association of 
polymorphisms in PDCD1 with systemic lupus erythematosus and rheumatoid arthritis 
(12-14). The most associated variant (designated PD1.3 or rs11568821) lies within intron 
4 of the gene and has been demonstrated to alter a RUNX1 transcription factor binding 
site rendering RUNX1 unable to bind to the PDCD1 sequences (12). Both the IFIH1 and 
PDCD1 genes encode transcripts that have widespread expression in lymphoid and other 
tissues, suggesting that they could have a role in many autoimmune conditions. In this 
study we have examined the IFIH1 Ala946Thr, and the PD1.3 SNPs in cohorts of 
Caucasians with GD and AAD to determine whether genomic polymorphism at these 
apoptosis-related loci may have a wider role in autoimmune endocrinopathy.  
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METHODS 
Materials and Methods 
Subjects 
The GD (n=602) probands were recruited through endocrine and thyroid associated 
ophthalmopathy clinics in Newcastle and the surrounding district hospitals. Of the 
Addison’s disease probands 105 were recruited from endocrine clinics in the North East 
of England, with a further 109 recruited via meetings of the UK Addison’s disease self-
help group (ADSHG). The diagnostic criteria for GD were biochemical hyperthyroidism 
with confirmation by either serum autoantibodies, radionuclide scan or presence of 
opthalmopathy (15). Of the GD probands 78% were female, 40% had significant thyroid 
associated ophthalmopathy (defined as NOSPECS class 3 or worse) and 55% were 
cigarette smokers. The Northeast AAD patients had a serum cortisol of less than 
550nmol/l following ACTH stimulation, with a raised basal plasma ACTH level, or 
pigmentation. Patients with tuberculosis, those with another known non-autoimmune 
cause, and those with autoimmune hypoparathyroidism or candidiasis (subjects with type 
1 polyendocrinopathy) were excluded from the cohort (16). AAD subjects recruited from 
ADSHG were all interviewed by CW or SHSP. A self-reported diagnosis of AAD in 
subjects with an appropriate medical history who were currently taking hydrocortisone 
and fludrocortisone was taken as evidence of AAD. The median age of onset, male to 
female ratio and prevalence of other autoimmune conditions was not different between 
AAD subjects recruited from our hospital services and from ADSHG. The AAD cohort 
included 161 females (75.2%) and 53 males (24.8%). Isolated AAD accounted for 36% 
of the AAD cohort, the other 64% had at least one other associated autoimmune disease 
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(hypothyroidism, 80; Graves’ disease, 25; primary gonadal failure, 24; type 1 diabetes, 
12; pernicious anaemia, 14; vitiligo, 6; celiac disease, 6; rheumatoid arthritis, 4; alopecia, 
3; haemolytic anaemia, 2; and autoimmune hepatitis, 1). UK controls (n=446; 66.3% 
females, 33.7% males) also recruited from the local population had no clinical features or 
family history of autoimmune disease. 
  
SNP genotyping 
Both the rs1990760 SNP in IFIH1 and the rs11568821 (PD1.3) SNP were genotyped 
using MALDI-TOF mass spectrometry of primer extension products (Sequenom iPlex 
system, Hamburg, Germany). Amplification primers, including tag sequences were as 
follows: rs1990760- ACGTTGGATGCTCCATGATGATTCTTTCCC and 
ACGTTGGATGTTTGATAGTCGGCACACTTC; rs11568821- ACGTTGGATGA 
GGCAGGCACACACATGGG and ACGTTGGATGCAACCTCAATCCCTAAAGCC. 
Extension primers were as follows: rs1990760- TTTACATTGTAAGAGAAAACAAA; 
rs11568821- CATTGGCCGGGCACCCCCGGAGAC. All reactions were carried out in a 
final volume of 5µl according to manufacturer’s conditions. Typing of ten percent of the 
samples was repeated blind to confirm assay fidelity.  
 
Statistical analysis 
The case-control association studies were analysed using χ2 tests on 2x2 and 2x3 
contingency tables for allele and genotype frequencies, respectively. Odds ratios and 
confidence intervals were calculated using Woolf’s method. Heterogeneity between the 
odds ratios in our study and those from the published analysis of T1D (9) was examined 
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using an interaction term in a logistic regression analysis. No significant deviation from 
Hardy Weinberg equilibrium was observed for either of the SNPs in this study (all 
p>0.05). We estimated that the power of our GD study was >90%, assuming an allelic 
odds ratio of 1.3 and an allele frequency of 0.40, as previous determined in UK controls 
at rs1990760 (α=0.05) (9). Assuming an OR of 1.16 (as previously found in T1D), we 
estimate that more than 900 probands and matched controls would be needed to give 80% 
power (α=0.05). 
 
 
RESULTS 
Both alleles and genotypes of the IFIH1 Ala946Thr (rs1990670) SNP were significantly 
associated with GD, with the Ala carrying allele being present in 796 of 1204 (66%) GD 
patient alleles compared to 508 of 892 (57%) control subject alleles; odds ratio 1.47 (5-
95% CI 1.23 to 1.76), p=1.9x10-5. In contrast, no association with alleles of the same 
marker was found in AAD. Full genotype and allele frequencies for the rs1990670 IFIH1 
marker are shown in table 1. 
 
In contrast, there was no association found in either the GD or AAD patient cohorts when 
compared to healthy controls at the PD1.3 SNP (rs11568821). The minor allele frequency 
being 11.6% in the healthy control subjects, compared to 10.3% in the GD patients and 
15.2% in the AAD cohort (full genotype and allele data are shown in table 2). 
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Heterogeneity testing according to the presence or absence of thyroid associated 
ophthalmopathy in the GD patients showed no significant difference in genotypes 
between the 2 groups for either marker (data not shown). Similarly, when comparing 
patients with isolated AAD to type 2 polyendocrinopathy, there were no significant 
differences in genotype frequencies at either locus (data not shown). 
 
 
DISCUSSION 
The first, exciting findings from a large-scale candidate variant study involving more 
than 6,500 non-synonymous single nucleotide polymorphisms in large cohorts of patients 
with type 1 diabetes revealed the IFIH1 gene as a novel locus (9). In our current study, 
we confirm that the alanine carrying allele at IFIH1 is also substantially associated with 
Graves’ disease (p=1.9x10-5). This result is important for several reasons. Firstly, more 
than any previous form of genetic linkage or association analysis, genome-wide 
association studies test out numerous markers and there is a possibility of generating 
highly significant false-positive results on account of the multiple hypotheses implicit in 
such a study. In the work of Smyth and colleagues (9), the positive association at IFIH1 
was found in 1,924 subjects with T1D and replicated both in a second cohort of 2,329 
T1D probands and in 2,134 trio families affected with T1D. While this initial analysis 
was robust by any standard, it is nevertheless still strongly reassuring to find that the 
association of autoimmune disease with IFIH1 alleles has now been independently 
extended to include another autoimmune disorder, Graves’ disease.  
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Secondly, IFIH1 is thought to have a role in protecting the host from viral infection by 
sensing viral nucleic acid in the cytoplasm and triggering a cellular anti-viral and 
apoptotic response (10,11). As Coxsackie and other enteroviral infections are 
epidemiologically linked to T1D incidence (17), it was suggested that IFIH1 
polymorphism could form a molecular link between the specific viral trigger and the 
autoimmune response in T1D (9). The finding of strong association of IFIH1 alleles with 
GD, a condition with no established link to viral infection suggests that IFIH1 might have 
an endogenous immunoregulatory effect, unrelated to any specific role as a viral receptor.  
 
Lastly, the association of IFIH1 alleles with GD in our population appears to be stronger 
than that with T1D, with an odds ratio for association of 1.47, in contrast to 1.16 found 
with T1D. While some of the variation in odds ratios may be stochastic, in particular 
relating to the slightly lower prevalence of the disease-associated alanine carrying IFIH1 
allele in our local healthy control population compared to the UK-wide controls used in 
the diabetes study (57.0% vs 59.6%), there may be a genuinely stronger effect of IFIH1 
in autoimmune thyroid diseases than in T1D, as has already been observed for alleles at 
the CTLA4 locus (18,19). Our analysis suggests that there is genuine heterogeneity in the 
strength of association at IFIH1 found in our GD cohort and in the T1D cohorts (an 
interaction term in a logistic regression was highly significant, p=10-16). Conversely, our 
study does not have the power to exclude a small effect of IFIH1 in autoimmune 
Addison’s disease pathogenesis. If the strength of effect in AAD is of the same order as 
that found in T1D (OR 1.16), more than 900 AAD probands and matched controls would 
be needed to show association. AAD is a relatively rare autoimmune endocrinopathy, 
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with a prevalence about 1 in 9000 in the UK (20) and sample cohorts of such a size 
currently do not exist. Collection and testing of such a larger Addison’s patient cohort 
would be a valuable future goal. 
 
In summary, this study confirms IFIH1 as a novel autoimmunity locus, extending its 
known role in type 1 diabetes to include a substantial role in Graves’ disease 
susceptibility. We can find no evidence to support an effect at the PDCD1 locus on 
susceptibility to either Graves’ or autoimmune Addison’s disease, underlining the 
differences in pathogenesis between these organ-specific autoimmune disorders and the 
non-organ specific disorders, where PDCD1 polymorphism has been shown to have a 
role. 
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Table 1. Genotype and allele frequencies for rs1990760 in Graves’ disease, Addison’s disease and healthy controls. 
 Genotypes Alleles P value a 
 AA AG GG A G Genotypes Alleles 
Allelic odds ratio 
(5-95% confidence 
intervals) a 
Controls 
(n=446) 
148 (33.2) 212 (47.5) 86 (19.3) 508 (57.0) 384 (43.0)    
Graves’ 
disease 
(n=602) 
266 (44.2) 264 (43.9) 72 (11.9) 796 (66.1) 408 (33.9) 1.4x10-4 1.9 x10-5 1.47 (1.23 to 1.76) 
Addison’s 
disease 
(n=204) 
69 (33.8) 105 (51.5) 30 (14.7) 243 (59.6) 165 (40.4) 0.35 0.38 1.11 (0.88 to 1.41) 
a.
 P values and odds ratios are shown for the each of the patient cohorts in comparison to healthy controls 
 
 
 
 
 
 - 16 - 
Table 2. Genotype and allele frequencies for rs11568821 in Graves’ disease, Addison’s disease and healthy controls. 
 Genotypes (%) Alleles (%) P value a 
 AA AG GG A G Genotypes Alleles 
Allelic odds ratio 
(5-95% confidence 
intervals) a 
Controls 
(n=432) 
6 (1.5) 88 (20.5) 338 (78) 100 (11.6) 764 (88.4)    
Graves’ 
disease 
(n=596) 
7 (1.2) 109 (18.3) 480 (80.5) 123 (10.3) 1069 (89.7) 0.66 0.37 1.13 (0.85 – 1.50) 
Addison’s 
disease 
(n=214) 
4 (1.9) 57 (26.6) 153 (71.5) 65 (15.2); 363 (84.8) 
 
0.17 0.07 0.73 (0.52 – 1.02) 
a.
 P values and odds ratios are shown for the each of the patient cohorts in comparison to healthy controls 
 
 
 
